Good afternoon, and welcome to the TransMedics Q3 2023 earnings conference call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Brian Johnston from the Gilmartin Group for a few introductory comments. Thank you. Earlier today, TransMedics released financial results for the quarter ended September 30, 2023. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call, including during the question and answer portion of the call, that include forward-looking statements within the meaning of federal securities laws. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including without limitation, our examination of operating trends, the potential commercial opportunity for our products, and our future financial expectations, which include expectations for growth in our organization and guidance into our expectations for revenue, gross margins, and operating expenses in 2023 and beyond, are based upon our current assumptions and estimates. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. Additional information regarding these risks and uncertainties appears under the heading Risk Factors on our Form 10-K, filed with the Securities and Exchange Commission on February 27, 2023. Our subsequent Form 10-Q filings and the forward-looking statements, including included in today's earnings press release, which is available on our website and at www.sec.gov. TransMedics disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 6, 2023. With that, I'll turn the call over to Waleed Hassanein, President and Chief Executive Officer. Thank you, Brian. Good afternoon, everyone, and welcome to TransMedics's Q3 2023 earnings call. As always, joining me today is Stephen Gordon, our Chief Financial Officer. The Q3 was an important foundation-building quarter for TransMedics. We closed two strategic acquisitions, one to position us for near-term growth with the Summit Aviation and one to position us for long-term growth with Bridge to Life Technologies. Following the acquisition of Summit Aviation in August, our team worked diligently to meet our goal to try to initiate a limited launch of our transplant logistics service in late Q3. We met this goal, and we started seeing early positive impact of logistics on revenue, on catalyzing NOP case volume, and overall clinical adoption. This early momentum, combined with sustained growth demand for all three organ markets and solid OUS performance, enabled us to achieve significant growth in Q3. This was achieved despite operational and resource challenges we outlined in our Q2 call. Here are the summary results for Q3. Our total revenue was $66.4 million, representing 159% growth over the same period in 2022, and 27% sequential quarter-over-quarter growth from Q2 2023. $64 million of the total of $66.4 million was from transplant-related activities, including approximately $2.1 million in NOP aviation and logistics-related revenue. We are thrilled by the early performance of our transplant aviation and logistics service, as it raises our confidence in our long-term plans, which I will cover later in the presentation today. Approximately $2.4 million of the total revenue was attributable to Legacy, Summit, Charter and flight school operations. As we've stated before, we intend to exit the Legacy charter business with diminishing contribution in Q4 before a full exit in early 2024. Meanwhile, we will maintain our flight school revenue, which will continue to be a part of our P&L going forward. Stephen will detail associated P&L impacts in his section of today's call. Our team did a great job executing on all fronts. Q3 performance speaks volumes to their hard work, dedication, and creativity. I want to take a moment and acknowledge our entire team at TransMedics for their efforts to help us achieve these great results. Now let me cover the specifics of Q3. In line with our growth strategy, we grew revenue across all three organ markets in the U.S. compared to Q2. OUS revenues also grew sequentially. Stephen will cover the detail in his section of today's call. Given the success of the NOP program and the flexibility it affords U.S. transplant programs to use it, going forward, we will primarily focus on the organ-specific revenue trends quarter-over-quarter instead of the number of centers. Let me repeat again. Going forward, we will primarily focus on organ-specific revenue trends quarter-over-quarter instead of the number of centers.... This is because we no longer believe or see center numbers as an accurate predictor of growth in the NOP era. Beyond strong revenue growth, we also demonstrated continued operational efficiencies in Q3, as we continue to benefit from increasing scale and making further progress towards positive cash flow and profitability. In terms of NOP, we met our stated goal of having NOP contribute the lion's share of our U.S. revenue in Q3, as we reached an all-time high of 97% NOP contribution of the total U.S. cases. On a per organ basis, approximately 98% of liver, 93% of heart, and 97% of lung cases were from NOP in Q3. Given this success, we fully expect that we will transition out of the shrinking direct acquisition model in 2024. To meet the growing demand for NOP and to overcome our clinical support staffing shortage we discussed in Q2, we added 45 new clinical specialists and 10 surgeons in Q3. We will continue to invest in this area throughout the remainder of 2023 and in early 2024 to prepare for the expected growth in 2024 and beyond. From a volume perspective, we are well on our way to reaching our stated goal of completing more than 2,000 U.S. NOP transplants in 2023. This would represent more than doubling of our case volume from 2022. Let me now turn to a more detailed discussion on our new logistics business. As we described on our Q2 call, TransMedics set out to develop a more efficient national transplant logistics model in the U.S. Our goal is to control the entire end-to-end process of donor to recipient logistics for all NOP transplant volume in the U.S. by the H2 of 2024. By way of background, and as a reminder, approximately 75%-80% of NOP heart, lung, and liver transplants require private charter air transportation to move transplant teams and organs from donor to recipients. The rapid expansion of NOP, the increase in distance afforded by the protective effect of the OCS technology, and our experience operating the NOP model in the U.S. over the past 18 months, have clearly shown us that the current industry model is inefficient and unscalable in the era of NOP and the new national allocation laws. Our vision is that with a TransMedics developed and operated world-class, efficient, transplant-dedicated logistics service, we can meaningfully drive additional growth of our NOP case volume and fueling overall revenue growth. Late in Q3, we initiated a limited launch of our new transplant logistics business with aviation to solve these inefficiencies and support and expand our NOP case volume. We are extremely pleased with the early results. Despite expected early growing pains and inefficiencies as we integrate the Summit operation, Q3 truly represents the first inning of this important new TransMedics business offering. So far, we are thrilled by the early encouraging results. We are in the process of building out the fleet and adding additional staff to operate the fleet efficiently. As of today, we have acquired eight planes. We plan to expand our fleet to around 15-20 operational planes by the H2 of 2024. Rest assured that we will continue to assess this need based on data-driven approach. We have also initiated the build-out of our logistics digital command and dispatch center in Andover, Massachusetts, and we expect it to be fully operational by Q1 of 2024. This is important, as it will drive significant efficiency to the dispatch operation for NOP clinical and logistical resources. I want to affirm that based on everything we know today, we are extremely confident and bullish on the potential positive impact of Transplant Logistics Service on the growth of our NOP case volume and more efficient utilization of our clinical resources. Before I move on from logistics and aviation, let me share our expectations on our gross margin progression going forward. In Q3, the inefficiencies associated with integrating Summit and streamlining the entire operation to focus on transplant, was a bit of a headwind on our service margin. We expect this to improve over the next few quarters. Let me be crystal clear. We fully expect both our product and service margins to improve over the next several quarters as we gain more operational leverage and efficiency. Simply stated, Q3 margins do not, I repeat, do not represent our long-term margins at all. The expected inefficiencies of integration. So, simply stated, Q3 margins do not represent our long-term margins at all, given the expected inefficiencies of integration and transitioning of the Summit operations. Now, let me turn to our mid- and long-term plans. As we stated in our last call, we have a multifaceted strategy to leverage some of the technologies we acquired from Bridge to Life to accelerate our OCS Next Gen program and expand our product offering. Our goal is to leverage these technologies and new clinical programs to drive our mid- and long-term growth in NOP case volume to reach our stated goal of performing 10,000 NOP cases in the U.S. by 2028. We hope to have more to share about these new technologies and its associated clinical programs later in 2024. We are continuing to drive our business forward, and for the seventh consecutive quarter, we have demonstrated that we can grow our revenue and adoption of our OCS NOP cases. We are on track to meet our stated goal of doubling our NOP transplants to more than 2,000 in 2023. We are not stopping here, however, as we are determined to reach our goal of 10,000 transplants over the next five years. Given our strong Q3 results, balanced with potential scalability challenges, we are increasing our annual revenue guidance for the full year 2023 to be between $222 million and $230 million, up from our previously communicated guidance of $180 million to $190 million, and representing 138%-146% growth over the full year 2022 total revenue. With that, let me turn the call to Stephen to cover the detailed financial results of the quarter. Stephen? Thank you, Waleed. I will now detail our Q3 results and provide supplemental financial information for the quarter. Given the two acquisitions and evolving business model, I will move through the dialogue carefully and try to touch on all relevant points. Starting with revenue. For the Q3 of 2023, our total revenue was $66.4 million. This is an increase of 159% from the Q3 of 2022, and a 27% sequential increase from last quarter. Of note, the $66.4 million of revenue for the quarter included $1.6 million of revenue related to Summit Aviation's legacy charter business. The legacy charter business is in the process of transitioning, and we intend to exit by early 2024. We expect the charter revenue should be minimal in Q4 and zero as we enter 2024. The $66.4 million of revenue also includes about $800,000 of revenue related to the flight school that was part of our acquisition of Summit Aviation. So taking into account the charter and flight school revenue, transplant-related revenue was $64 million. Now, as Waleed mentioned, included in this $64 million was our first transplant-related logistics revenue of $2.1 million. This logistics revenue was derived from missions that utilized our own logistics network. In the past, our hospitals, our hospital customers would have paid this to other logistics brokers, but this is now part of the service that we are providing. So we feel that $2.1 million in less than a full quarter is a very good start. In the U.S., U.S. transplant revenue for the quarter was $59.7 million. That's 156% growth from Q3 of 2022, and this includes the $2.1 million of logistics revenue. The organ breakdown on U.S. revenue was $41.2 million of liver, $15.1 million of heart, and $3.4 million of lung. So let me just repeat that. $41.2 million of liver, $15.1 million of heart, and $3.4 million of lung. Ex-U.S. revenue was $4.3 million. It was $3.9 million of heart, $0.3 million of lung, and $0.1 million of liver. Now, regarding the breakout of product and service revenue this quarter. Service revenue is growing given the introduction of logistics and aviation. So product revenue was $47.7 million in Q3 of 2023, and service revenue was $18.7 million. Just reiterating, the service revenue includes the $2.4 million of non-transplant related revenue as part of the Summit acquisition, $1.6 million of the charter that's being transitioned out by 2024, early 2024, and $0.8 million of the flight school revenue. This we expect to recur, but it's not likely to grow. So the flight school will be less material as our transplant revenue grows. Now, turning to gross margin. Gross margin for the Q3 of 2023 was 61%. And as Waleed mentioned, this is lower than the Q2 of 2023 due to transient inefficiencies related to the Summit acquisition and limited launch of our transplant logistics offering. Beyond the integration, margin was also unfavorably impacted by legacy charter operations as we transition to focus exclusively on transplant missions. So our service margin was impacted by both of these. We had the old charter business trailing off, and we have the new transplant business beginning, but neither one was at scale in the quarter. In general, the higher mix of service does reduce the overall business gross margin. However, we fully expect the gross margin to improve in the coming quarters. In simple and mathematical terms, our product margin this quarter was 77%, and we expect this to improve into the 80% range over the next few quarters... And the service margin was 21% in Q3. We also expect this to improve over the next few quarters to the low-to-mid 30% range. The mix in the quarter was 72% product and 28% service. In the future, we expect the mix to be about 70/30 product and service, which would equate to about a mid- to upper-60% range for gross margin in the overall business, very much in line with our expectations. So we do expect, and are very confident, that the gross margin will improve over the next several quarters, starting in Q4 and into 2024. Given the higher mix of service in our business, we believe a mid- to upper-60s gross margin is a reasonable, steady state. Of course, as our logistics allows us to open up more cases and more product sales, the overall gross profit dollar contribution will be significantly higher than if we were not using our own logistics network. And this was true in this quarter, Q3, that we just finished as well. Moving on to expenses. Total operating expenses for the Q3 of 2023 were $69 million. However, operating expenses include two acquisition transition, excuse me, two acquisition transaction-specific impacts. First, we have $27.2 million of acquired in-process research and development expenses related to our acquisition of the Bridge to Life technologies. And secondly, included in SG&A is approximately $2.2 million of other acquisition-related expenses. Now, if we normalize for these two items, our underlying operating expense was $39.8 million. This is 68% above the Q3 of 2022 and 6% sequential growth from Q2 of 2023. We have continued to make critical investments in the company to ensure scalability for growth and to support future growth, while still growing expenses at a much lower rate than revenue. Our operating loss was $28.3 million in the quarter of 2023, compared to $5.5 million in the Q3 of 2022. Taking into consideration the two transaction-specific expense items I mentioned earlier, our operating income would have been just above break even for the quarter, about $900,000. Our net loss for the Q3 of 2023 was $25.4 million, compared to $7.4 million in the Q3 of 2022. Total cash was $427.1 million as of September 30, 2023. In the quarter, we spent $42.1 million on the two business acquisitions, as well as approximately $103 million on eight jets that were added to our transplant logistics fleet. We are depreciating these jets over 10 years with a 50% residual value. Finally, weighted average common shares outstanding for the quarter were 32.6 million. Overall, we are extremely pleased with our Q3 financial results. We have demonstrated that adding our own aviation and logistics offering in Q3 allowed us to continue growing revenue at a strong pace. While we saw some headwinds on gross margin in this transitional quarter, I have full confidence in our ability to grow the gross margin to the mid-60s%, as we have described, after integrating our logistics offering. This change in our business also show that even with a lower gross margin, the gross profit dollars are growing, which clearly puts us on a path to profitability. As a concluding statement, I will repeat our updated revenue guidance of $222 million-$230 million for 2023, which represents 138%-146% growth. Now I would like to turn the call back to Waleed for closing statements. Thank you, Stephen. Overall, the Q3 was a critical execution period for TransMedics as we integrated a new business, Summit Aviation, expanded our NOP clinical support capacity, and launched a first-of-its-kind business to expand our NOP product and service offering. Despite the great results achieved, we firmly believe that we are setting up a great foundation to further accelerate our growth in 2024 and beyond. We are extremely confident in our strategy and our ability to execute it to achieve our stated goal of 10,000 NOP transplant missions by 2028. With that, I will now turn the call to the operator for Q&A. Operator? We will now begin the question-and-answer session. To ask a question, you may press star, then one on your touchtone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then two. At this time, we will pause momentarily to assemble our roster. The first question comes from Allen Gong with JPMorgan. Please go ahead. Hi, can you hear me okay? Yes. Hi, Allen. I just want to make sure my line dropped for a second. Congratulations on the really good quarter. Just kind of, you know, to touch on it a bit, just the guidance, right? You know, just kind of doing my math, it looks like you're guiding to basically flat growth in Q4, and you had highlighted that you were, you know, taking a little bit of a cautious stance on a few dynamics. So can you walk us through kind of, you know, what is leading to, you know, that caution? Is it the trends you're seeing so far in October, or is it just, you know, the logistics of ramping up your aviation service model? It's certainly the latter, Allen. Two things. One, we are not fully staffed yet. We made significant progress in Q3. Our team was extremely creative to make us achieve the results we achieved, but we're not out of the woods yet. So that's number one. Number two, is continuing to standing up the aviation business. Actually, what we've seen in October is actually extremely encouraging. We just need to make sure that we are cautious in our guidance to make sure that we still have these operational challenges for the rest of this year. Got it. And then, you know, I, I'm guessing it's probably a little early to be talking about 2024, but, you know, I think in the past, you've talked about your ambition. You know, you obviously have your ambition for 2028, but when we think about, you know, the near term, you've talked about really wanting to continue doubling, you know, sales and number of transplants. So when we think about 2024, with the fact that not only will you have continued momentum in the organ business, but now also a ramping contribution from aviation, how should we think about, you know, your growth aspirations for 2024? Thank you. Thank you, Alan. Alan, we are not shy of sharing our aspiration and our ability to execute upon it. However, your reference point needs to be updated a little bit. We've tripled our revenue last year. We are on pace to double this year over last year. I think we will issue guidance for 2024 in an end-of-year call, but I wanna be, you know, cautioned that our numbers are growing significantly. So, you know, that data point is a bit dated, so... But we're not issuing any guidance for 2024 right now. We will do it in the first call in the year. Our next question comes from Bill Plovanic with Canaccord. Please go ahead. Great, thanks for taking my questions. Good evening, and, congratulations on a strong quarter. First, I think, you know, the most questions we're getting these days are related to the metrics surrounding the aviation business. I think you gave us a little color on the gross margin, but, you know, of the whole services business, can you give us an idea of, you know, what you think kind of average revenue per case is, gross margin, operating margin per case? And then I think you projected, or you said that maybe 75%-80% of your current NOP could be with your own aviation applicable to that. Just trying to get some metrics around this so we can kind of model this out. Thanks. Thanks, Bill. It's way too early to focus on that nitty-gritty details on the aviation. And we don't intend to share that anytime soon. Our most indicative metric to track is growth in revenue and improvement in the service margin. That's what we are gonna be focusing on, and we believe it's the most indicative of healthy operation both from the service and the product revenue. On the second one, of course, our intention is to cover almost 100% of our NOP cases with our aviation, but we have to be realistic. We would need, you know, we need to make sure that we beef up the fleet first, get all of our support staff, the pilots, the dispatch operations stood up. That's why we expect to be doing the lion's share of the NOP cases by the H2 of next year, not before then. But our goal is to do as many of those cases ourselves, given, of course, what we see as a huge benefit, you know, on all fronts when we do that. I mean, we don't have visibility into the metrics, but just ballpark, on average, what's a typical case revenue that you've seen kind of push through, you know, the hospitals to reimburse for an average case on a revenue for aviation specifically? How should we think about that? Sure. So Bill, I wanna be cautious. This is not a question, this is a fact of organ transplant. All aviation and logistics transport are fully reimbursed through the same mechanism of organ acquisition. There's no limit per se. In fact, we're doing this because we believe we could be more efficient and pass some of the efficiencies back to the transplant program. So I do not want anybody on this call to think that the aviation business is not reimbursed through normal mechanisms of organ transplant. There is no limit. There is no specifics. If the center feels that it's too expensive, they would ask for another quote or get from another vendor. But it's fully reimbursed. It's not a question of reimbursement, it's a question of making sure that we have the fleet, the efficiencies, the support team to be able to cover the missions. As far as the average, again, it's too early. It depends if you're flying, you know, shorter distances, the average is, you know, somewhere between $25,000-$30,000. If you're flying longer distances, it could go as high as $100,000. So it's really, it depends on what type of missions you're flying, and again, we... Our goal is to gain efficiencies first, gain volume. The Q3 results is just really the first inning, not even early innings, it's the first inning. We're looking forward to, you know, achieving more, building more confidence and sharing more detail as we build the fleet and build up the operational efficiency we are foreseeing here. Then last question, I promise, just on the fleet, you know, a couple of things. One, you ended the quarter with $427 million in cash. I think there's been 8-Ks. You've acquired 8 planes, and if my memory serves me correct, you are looking to acquire eight more, you know, which 427, if it's $12 million a plane, that'll leave you with, you know, over $300 million in cash. And I think, not to take words out of Stephen's mouth, but, your core business, stripping everything out, was actually profitable by almost $1 million. Am I missing something here? Does that math add up? You're not missing anything, Bill. This is Stephen. You got it exactly right. Awesome. Thanks for taking my questions. Thank you, Bill. The next question comes from Suraj Kalia with Oppenheimer. Please go ahead. Hi, Waleed, Stephen, can you hear me all right? Yes. Hi, Suraj. Gentlemen, congrats on a great quarter. So Waleed, I know you're shying away for obvious reasons from giving some of these metrics, but I have to ask. Waleed, give us some idea, in your prepared remarks, you mentioned that your team was creative in meeting demand. Help us understand, you know, in terms of dry runs and missed runs, how should we think about that? How did y'all handle that in this quarter, particularly? Sure. Thank you, Suraj. My prepared remarks really was addressing the fact that, yeah, you know, we were able to achieve these great results despite the fact that we were still building our clinical support team. So really, our team went out of their way to make sure that we cover as many of the cases as we can and minimize the impact of limited clinical staffing on our performance. That's one aspect of it. The second aspect is of our logistics team. We were operating with very, very small fleet and very small staffing, and we went out of the way to make sure that we cover those cases efficiently as much as we can, and the results speak for themselves. So that's really what the prepared remarks was intending to show. As far as the rate of dry runs, the dry runs, as I stated several times, dry runs is the nature of the DCD donation. You know, it's gonna be with us. As long as we have DCD donors, there's always gonna be a case where the DCD or potential DCD donor doesn't progress to DCD. You know, and as long as we're using DCD donors, this is gonna be the norm for us as we go forward. As far as the trend we saw in the quarter, I would say it was the rate of DCD donors progressing or lack of progression of DCD donors was a little bit below Q2, but that's all I can comment on. But there's always DCD lack of progression when you're using DCD donors. Waleed, for my second question, I know when we were at your, at, during the site visit, if memory serves me right, you had indicated that, you know, 70% or north of 70% of all DCD hearts were, you know, TransMedics was capturing those. I, I, I'd love to get some updated color from you, especially in hearts. How do DCD and, and DBD trajectories look like? If you could also characterize how you think TransMedics' share progression within these subcategories is moving. Gentlemen, thank you for taking my questions. Congrats again. Thank you, Suraj. I appreciate the call. I appreciate the question. So let me address the two-part question you asked. The first is, yes, TransMedics continue to do the lion's share of DCD heart donation in the United States. We expect to release the, annualized number, after, at, by year-end, when the full number of DCD hearts, are released, but from where we see it here, we are continuing to be north of 70%, for sure. As I stated, many times publicly, DCD is the low-hanging fruit right now, because it's the sort of the black and white option to growing U.S. transplant volumes. That's why we expect to see the overall heart, lung, and liver transplant to grow this year over last year, because of the high use of DCD donors, especially in heart and livers, that is afforded by OCS. Now, that doesn't mean that DBD will not, you know, the DBD is not being used. The opposite is true. I would say so far, it's between 45%-50% of our volumes are DBD. We expect to see that growing into in 2024 and beyond, as we are now highlighting the benefits. There will be some data readouts. There are some publications coming up in early 2024 that will clearly point out the importance of using DBD organs to expand the donor pool even further. So we are confident that as we move forward, the DBD and DCD portion of our business will continue to grow, and we'll continue to achieve the, you know, high success rates on both. ... Appreciate it. Our next question comes from Ryan Daniels with William Blair. Please go ahead. For you there, I know there was a little bit of controversy on NRP over the last few quarters and just demand in the market with DCD for that. But we've actually heard recently in our channel checks that many systems, especially nonprofits, are just banning NRP outright due to ethical issues. So I'm curious if you've seen that in the market where that's actually starting to face some bans across the United States. Hi, Ryan. As I stated last call, and you're absolutely right, we are not concerned at all about the progression of NRP. We are seeing the opposite is true. We're seeing many centers that uses NRP are now, or used to use NRP, are now shifting to OCS. Again, we are doing more than 70% of the DCD hearts in the United States, so I'm not concerned at all. NRP is gonna be, you know, it's gonna be limited in nature. We have, you know, our results is pointing to that. And we have a couple of abstracts at the upcoming ISHLT that will address this point directly and clearly show that the importance of OCS and capabilities of OCS, including cost comparison between OCS and NRP. Because for a while there was a misunderstanding, a misnomer, that OCS might be more expensive than NRP. The opposite is true. TransMedics... The bottom line is TransMedics is doing the lion's share of DCD hearts in this country. We expect that to continue to be the case, and ultimately, at some point, we'll probably be doing the vast majority of it. We are proud with where we are. We trust our technology, we trust our methods, because it eliminates all these ethical and legal concerns that exist around NRP. Gotcha. That's, that's super helpful,. And then I guess the additional question, and I'll hop back in the queue. Really good progress adding clinical staff. I think you said 45 new clinical staff and 10 surgeons. Can you speak a little bit to how that progressed through the quarter? Did you see the benefit for the full quarter, or was that, you know, kind of spread throughout the quarter? And then how should we think about the investments there in the Q4 to get to the scale you need to continue to grow into 2024? Thank you, and congrats again. Thank you, Ryan. I think, you know, to be fair, I think this came through, mainly through the H2 of the quarter, so they contributed some, but not significantly. We expect those to contribute more in Q4, and we will continue to make investment in building out the clinical support staffing in Q4 to prepare for 2024 and beyond. So this is a, this is a, this is gonna be a fountain that doesn't stop giving, because as we see more and more growth, we would need more and more clinical support staffing. And Tamer and his team are doing a great job in getting them trained and deployed to the field. But we will see the impact of these 45 new hires in Q4. As we, you know, ramp up in Q4, it's mainly to see the impact in early 2024. Okay, perfect. Thank you so much. Our next question comes from Josh Jennings with TD Cowen. Please go ahead. Thanks, William and Stephen. Congrats on the really strong results. Wanted to just ask on two things, William, you said on your prepared remarks. I I think the first with just the center numbers, you don't believe it's an accurate predictor of growth anymore. Hope I'm not asking you to repeat yourself on some of the other questions that you've answered already, but can you just give us a little bit more detail on why center numbers are not an accurate predictor of growth, and just build on that download? Sure. Thank you, Josh. Really, what I meant by saying that, Josh, is, as long as we're growing our revenue per organ segment, quarter-over-quarter, that is the, for us, that is the most, strongest indicator of our growth. With NOP, as you know, I mean, every quarter, we get a handful of centers that never use the OCS in their life, in our life, and they jump in into the NOP. Most of those continue and grow, but some of them may they, they slip a month, and, and then come back again. Some, you know, some continues every month. It, it's... All I'm trying to say is, it's becoming noisy to be looking at the center to center, quarter-to-quarter center growth. The other thing is, that's the most important, is for liver and heart, we're already at a critical mass of centers. We're already north of 40 centers per heart and liver. So it's, you know, growing beyond that is mostly growing within the center, i.e., increasing the adoption and penetration within the center. That's that's important. The lung, until we have a new clinical program in lung, it's gonna be fewer centers doing the lung, but this quarter was the largest anyway, and it's reflective of the lung revenue. That's what we're saying. We wanna be not confusing the market with too much data that really may not track the growth. The growth is tracked by the quarter-to-quarter progression of per organ revenue. That is the most accurate indicator of growth. ... And can we read through that, on that commentary that, you know, that you were reporting regular users versus centers that have as well as the metric of centers that have enlisted TransMedics and with the NOP service in the quarter. But is that, with capacity expanding, that delta and those metrics just not important and, as you said, not an accurate predictor of growth? Exactly. That's exactly what we're saying, Josh. Great. Um. Great. Excellent. My follow-up is with something that we talked about, I think, at a headquarters visit this quarter. I think just in my notes, I had you saying that the payers are saving money with NOP cases, and there's a desire from payers for centers to adopt NOP and use TransMedics as that service. We're hoping you could just build on that and just how much interaction does your company, TransMedics have with payers and anything you can add just to that, payers are saving money with each NOP case? Thanks a lot. Sure. Thank you, Josh. Let me clarify Josh's question. The comments we made during the team from TD Cowen’s visit here is absolutely true. What we're referring to is with NOP, the growth of NOP have demonstrated the significant economic benefit of using OCS NOP across the chain of organ for a patient needing an organ transplant. Starting with accessing more organ lowers the patient wait time on the waiting list. That's one of the biggest cost driver to insurance companies, keeping patients waiting on the waiting list in an ICU environment, sometimes even supported, maximum supported in an ICU environment. So that's number one. Number two, we're seeing the post-transplant surgical procedures that cost, add additional cost to the case rate dropping significantly. For example, post-transplant bleeding, post-transplant take down to the OR, post-transplantation, post-transplant procedures like ESCP is going down, significantly. And that's what's causing the payers to say, "We're seeing the benefits of..." It's really driven by more organs. With more organs, you're really driving the cost efficiency or the health economics of an organ transplant, significantly to a transplant payer. And that's what we're seeing and what we're hearing. We are in constant communication and dialogue with some of the major payers in the United States. However, we're seeing more and more centers now are picking up that mantle and having their own discussion with their own business cases to their payers with significant success. We just held multiple forums here in Boston in mid-October, and many programs highlighted to the rest of the community their success in growing their transplant volume from OCS and their positive discussion with payers, commercial payers, given the significant success they've achieved in growing their volume. So we continue to believe that this is going to continue with us, and the key for us is to make sure that we continue to laser focus on outcomes and the quality of care we're providing. If we do that right, the rest is going to be a pretty straightforward execution challenge. You got that one. Thanks, Waleed. The next question comes from Bill Plovanic with Canaccord Genuity. Please go ahead. Great, thanks. Actually, I tried to get back out of the queue, but you've answered my question. Thanks. Thanks, Bill. This concludes our question and answer session. I would like to turn the conference over to Waleed Hassanein. Hassanein. For any closing remarks. Thank you so much for your time this evening, and we're looking forward to following up and looking forward to our next call. Thank you. Have a great evening, everyone. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.